Bio-Techne
NASDAQ: TECH
Stock price
72.12 USD
(+Infinity%) NaN day
Financial Performance
5Y price score: (51)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 171.6%
US$ Per
Share
By default your notes are visible only to you.
43.2
52-week range
72.1
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2.4 %
Dividend Yield TTM
0.4 %
Market cap $
$ 11,292
Price / Earnings TTM
104.5
Price / Book TTM
5.4
PEG TTM
(1.9)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
35.9 %
(35.7) %
171.6 %
Free cash flow per share growth
9.4 %
65 %
100.3 %
Earnings per share growth
(56.2) %
(68.3) %
(36.1) %
Founded: 1,976
Employees: 3,100
Business Summary:
Latest Earnings Call Takeaways
2026 Q3 (May 6, 2026)
1) Strategy & Leadership - Bio-Techne is focusing on operational discipline amidst a dynamic market environment. - The company is streamlining its brand portfolio from 10 brands to 3, enhancing customer engagement across research to clinical applications. - The leadership team is optimistic about fiscal 2027, citing encouraging indicators in U.S. academia and emerging biotech recovery.
2) Financial & Segment Results - Q3 total revenue was $311.4 million, down 2% YoY; organic revenue declined 2%, but underlying growth was 2% after adjusting for specific headwinds. - Adjusted EPS was $0.53, down $0.03 YoY; GAAP EPS improved to $0.32 from $0.14. - Segment performance: - Protein Sciences: Revenue declined 4% organically, but grew nearly 50% YoY when excluding cell therapy customer impacts. - Diagnostics & Spatial Biology: Achieved 3% organic growth, with COMET platform growing over 65%.
3) Problems / Headwinds - Emerging biotech spending continues to decline, with a high single-digit drop in revenues, reflecting a lag in spending following funding constraints from 2025. - Order timing issues related to cell therapy customers created a 400 basis point headwind in Q3. - The company anticipates flat organic growth in Q4, primarily due to ongoing challenges in the biotech sector.
4) Operational or Product Plans - Bio-Techne is leveraging AI to enhance protein design and improve operational efficiency. - The company is focused on expanding its Spatial Biology and Proteomic Analysis platforms, with strong growth expected in these areas. - Continued investment in cell therapy and diagnostics is planned, with a focus on maintaining high profitability.
5) Guidance & Outlook / Investor Angle - The company expects low single-digit underlying growth in Q4, with a more optimistic outlook for fiscal 2027 as funding conditions improve. - The anticipated recovery in biotech spending is expected to materialize in the first half of fiscal 2027, driven by increased funding and easing headwinds. - The leadership remains confident in the company’s ability to achieve mid-single-digit growth in fiscal 2027, supported by strong positions in core segments.
Bottom line: Bio-Techne is navigating a challenging market landscape but is well-positioned for recovery in fiscal 2027, with strong growth in key segments and a focus on operational efficiency. Investors can expect gradual improvement as funding conditions stabilize and customer spending increases.
Annual Reports, Presentations And IR Contacts
Go to the websiteBio-Techne — Financial Overview, Stock Price, Market Cap
Bio-Techne is a company. Founded in 1976. As of July 20, 2026, the company's market capitalization is $11291756280 with a current stock price of $72.12.